EKF Diagnostics Tightens Share Capital With Targeted Buyback

EKF Diagnostics Holdings ( (GB:EKF) ) has provided an announcement.

EKF Diagnostics Holdings has repurchased 213,000 ordinary shares at 25 pence each, which will be held in treasury, reducing the number of shares in public hands and leaving 431,396,112 shares carrying voting rights. The transaction includes the acquisition of 63,000 shares from funds managed by Harwood to ensure non-executive director Christopher Mills’ aggregate indirect interest remains around but not above 30% of total voting rights, a move that fine-tunes the company’s capital structure and preserves its shareholder control profile.

Following this buyback, EKF’s issued share capital stands at 431,963,112 ordinary shares, of which 567,000 are held in treasury, a level that may affect calculations for shareholders monitoring disclosure thresholds under FCA rules. The carefully structured purchase from Oryx International Growth Fund and North Atlantic Smaller Companies Investment Trust aligns with regulatory considerations around significant shareholdings, signalling active management of governance and ownership concentration within the AIM-quoted diagnostics group.

The most recent analyst rating on (GB:EKF) stock is a Hold with a £26.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Spark’s Take on EKF Stock

According to Spark, TipRanks’ AI Analyst, EKF is a Neutral.

EKF Diagnostics Holdings receives a score of 67, driven by strong financial performance and a positive earnings call. The company’s robust balance sheet and improved profitability are significant strengths. However, technical indicators suggest potential bearish momentum, and the valuation is moderate. The positive outlook from the earnings call, including strategic growth plans and a share buyback program, enhances the overall score.

To see Spark’s full report on EKF stock, click here.

More about EKF Diagnostics Holdings

EKF Diagnostics Holdings is an AIM-listed global diagnostics business headquartered in Penarth, near Cardiff, with five manufacturing sites across the U.S. and Germany. The company focuses on point-of-care analysers in hematology and diabetes, as well as life sciences services manufacturing specialist enzymes and custom products for diagnostic, food and industrial applications, selling into more than 120 countries worldwide.

Average Trading Volume: 327,328

Technical Sentiment Signal: Sell

Current Market Cap: £108.8M

See more insights into EKF stock on TipRanks’ Stock Analysis page.